Use of inhaled GM-CSF in treatment-refractory NTM infection. An open-label, exploratory clinical trial.
R. Thomson (Brisbane, Australia), G. Waterer (Perth, Australia), M. Loebinger (London, United Kingdom), C. Ganslandt (Hørsholm, Denmark)
Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Thomson (Brisbane, Australia), G. Waterer (Perth, Australia), M. Loebinger (London, United Kingdom), C. Ganslandt (Hørsholm, Denmark). Use of inhaled GM-CSF in treatment-refractory NTM infection. An open-label, exploratory clinical trial.. 1603
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012
Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 674s Year: 2007
Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial Source: ERJ Open Res, 6 (4) 00534-2020; 10.1183/23120541.00534-2020 Year: 2020
A randomized, controlled, open-label study to evaluate the efficacy and safety of oral lopinavir-ritonavir in adults hospitalized with COVID-19 virus infection Source: Virtual Congress 2020 – Chinese programme 2020: Part I Year: 2020
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
Open-label, randomized, comparative trail of the efficacy of the azithromycin in the 8-week treatment of mild-to-moderate asthma Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007
RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007
Analysis of the efficacy of moxifloxacin for the treatment of bronchial colonization in COPD patients using microbial molecular typing: a randomized, double-blind, placebo-controlled study Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
Supplementation of N-acetylcysteine as an adjuvant in treatment of newly diagnosed pulmonary tuberculosis patients: A prospective, randomized double blind, placebo controlled study Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID Year: 2021
Efficacy of a short course of oral prednisolone for acute preschool viral-wheeze: a double-blind randomised placebo-controlled trial with stratification for systemic eosinophil priming Source: Eur Respir J 2003; 22: Suppl. 45, 388s Year: 2003
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001
Tocilizumab treatment for patients with Covid-19 pneumonia - a single centre observational study Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021